Home > Publications database > E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. > print

001     132818
005     20240229105034.0
024 7 _ |a 10.1038/s41598-018-23733-4
|2 doi
024 7 _ |a pmid:29700408
|2 pmid
024 7 _ |a pmc:PMC5920115
|2 pmc
024 7 _ |a altmetric:40654579
|2 altmetric
037 _ _ |a DKFZ-2018-00462
041 _ _ |a eng
082 _ _ |a 000
100 1 _ |a Horne, Hisani N
|b 0
245 _ _ |a E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium.
260 _ _ |a London
|c 2018
|b Nature Publishing Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1659949713_8494
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a E-cadherin (CDH1) is a putative tumor suppressor gene implicated in breast carcinogenesis. Yet, whether risk factors or survival differ by E-cadherin tumor expression is unclear. We evaluated E-cadherin tumor immunohistochemistry expression using tissue microarrays of 5,933 female invasive breast cancers from 12 studies from the Breast Cancer Consortium. H-scores were calculated and case-case odds ratios (OR) and 95% confidence intervals (CIs) were estimated using logistic regression. Survival analyses were performed using Cox regression models. All analyses were stratified by estrogen receptor (ER) status and histologic subtype. E-cadherin low cases (N = 1191, 20%) were more frequently of lobular histology, low grade, >2 cm, and HER2-negative. Loss of E-cadherin expression (score < 100) was associated with menopausal hormone use among ER-positive tumors (ever compared to never users, OR = 1.24, 95% CI = 0.97-1.59), which was stronger when we evaluated complete loss of E-cadherin (i.e. H-score = 0), OR = 1.57, 95% CI = 1.06-2.33. Breast cancer specific mortality was unrelated to E-cadherin expression in multivariable models. E-cadherin low expression is associated with lobular histology, tumor characteristics and menopausal hormone use, with no evidence of an association with breast cancer specific survival. These data support loss of E-cadherin expression as an important marker of tumor subtypes.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Oh, Hannah
|b 1
700 1 _ |a Sherman, Mark E
|b 2
700 1 _ |a Palakal, Maya
|b 3
700 1 _ |a Hewitt, Stephen M
|b 4
700 1 _ |a Schmidt, Marjanka K
|b 5
700 1 _ |a Milne, Roger L
|0 0000-0001-5764-7268
|b 6
700 1 _ |a Hardisson, David
|0 0000-0002-2183-3699
|b 7
700 1 _ |a Benitez, Javier
|b 8
700 1 _ |a Blomqvist, Carl
|b 9
700 1 _ |a Bolla, Manjeet K
|b 10
700 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 11
700 1 _ |a Chang-Claude, Jenny
|0 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
|b 12
|u dkfz
700 1 _ |a Cora, Renata
|b 13
700 1 _ |a Couch, Fergus J
|b 14
700 1 _ |a Cuk, Katarina
|0 P:(DE-He78)0a8ada1f5d2ea05fc3af10cd808bfa9a
|b 15
|u dkfz
700 1 _ |a Devilee, Peter
|b 16
700 1 _ |a Easton, Douglas F
|0 0000-0003-2444-3247
|b 17
700 1 _ |a Eccles, Diana M
|b 18
700 1 _ |a Eilber, Ursula
|0 P:(DE-He78)cffd553d01599230a3c71996e452ca75
|b 19
|u dkfz
700 1 _ |a Hartikainen, Jaana M
|b 20
700 1 _ |a Heikkilä, Päivi
|b 21
700 1 _ |a Holleczek, Bernd
|b 22
700 1 _ |a Hooning, Maartje J
|b 23
700 1 _ |a Jones, Michael
|b 24
700 1 _ |a Keeman, Renske
|b 25
700 1 _ |a Mannermaa, Arto
|b 26
700 1 _ |a Martens, John W M
|0 0000-0002-3428-3366
|b 27
700 1 _ |a Muranen, Taru A
|b 28
700 1 _ |a Nevanlinna, Heli
|0 0000-0002-0916-2976
|b 29
700 1 _ |a Olson, Janet E
|b 30
700 1 _ |a Orr, Nick
|b 31
700 1 _ |a Perez, Jose I A
|b 32
700 1 _ |a Pharoah, Paul D P
|0 0000-0001-8494-732X
|b 33
700 1 _ |a Ruddy, Kathryn J
|b 34
700 1 _ |a Saum, Kai-Uwe
|0 P:(DE-He78)97343bbd9545a4b87574e74329dabfd1
|b 35
|u dkfz
700 1 _ |a Schoemaker, Minouk J
|b 36
700 1 _ |a Seynaeve, Caroline
|b 37
700 1 _ |a Sironen, Reijo
|b 38
700 1 _ |a Smit, Vincent T H B M
|b 39
700 1 _ |a Swerdlow, Anthony J
|b 40
700 1 _ |a Tengström, Maria
|b 41
700 1 _ |a Thomas, Abigail S
|b 42
700 1 _ |a Timmermans, A Mieke
|b 43
700 1 _ |a Tollenaar, Rob A E M
|b 44
700 1 _ |a Troester, Melissa A
|b 45
700 1 _ |a van Asperen, Christi J
|b 46
700 1 _ |a van Deurzen, Carolien H M
|b 47
700 1 _ |a Van Leeuwen, Flora F
|b 48
700 1 _ |a Van't Veer, Laura J
|b 49
700 1 _ |a García-Closas, Montserrat
|b 50
700 1 _ |a Figueroa, Jonine D
|0 0000-0002-5100-623X
|b 51
773 _ _ |a 10.1038/s41598-018-23733-4
|g Vol. 8, no. 1, p. 6574
|0 PERI:(DE-600)2615211-3
|n 1
|p 6574
|t Scientific reports
|v 8
|y 2018
|x 2045-2322
909 C O |p VDB
|o oai:inrepo02.dkfz.de:132818
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)0a8ada1f5d2ea05fc3af10cd808bfa9a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-He78)cffd553d01599230a3c71996e452ca75
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 35
|6 P:(DE-He78)97343bbd9545a4b87574e74329dabfd1
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Cancer risk factors and prevention
|x 0
914 1 _ |y 2018
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b SCI REP-UK : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b SCI REP-UK : 2015
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
920 1 _ |0 I:(DE-He78)G110-20160331
|k G110
|l Präventive Onkologie
|x 1
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 2
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a I:(DE-He78)G110-20160331
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21